Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, randomized, placebo-controlled evaluating Sanbexin ® combined with thrombectomy in treatment of patients with moderate-severe stroke treated with Endovascular thrombectomy

Next Previous
X
Search
Trial Profile

A multicenter, double-blind, randomized, placebo-controlled evaluating Sanbexin ® combined with thrombectomy in treatment of patients with moderate-severe stroke treated with Endovascular thrombectomy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Stroke
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Oct 2024 New trial record
    • 25 Oct 2024 According to Simcere Pharmaceutical Group media release, data of this trial was published in an oral report at the 16th World Stroke Conference (WSC) brain cell protection combined with edaravone dexborneol (Sanbexin ) in patients with acute ischemic stroke before endovascular thrombectomy significantly improved the proportion of patients who recovered neurological independence at 90 days and reduced the proportion of patients with disability.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top